Long‐Term Safety and Efficacy of Repeat Treatments with <scp>DaxibotulinumtoxinA</scp> in Cervical Dystonia: Results from the <scp>ASPEN</scp> ‐Open‐Label Study
DAXI was safe and efficacious over repeated treatments in adults with CD. Adverse event rates were similar to or potentially lower compared with conventional BoNTs.
Authors
- Sebastian Paus (ORCID: https://orcid.org/0000-0003-0707-2421)
- Aaron Ellenbogen (ORCID: https://orcid.org/0000-0002-4086-8336)
- Todd M. Gross (ORCID: https://orcid.org/0000-0001-5482-5313)
- Conor J. Gallagher (ORCID: https://orcid.org/0000-0002-5488-6594)
- Atul T. Patel (ORCID: https://orcid.org/0000-0003-2765-7953)
- Jarosław Sławek (ORCID: https://orcid.org/0000-0001-6816-0877)
- David Hollander
- Rashid Kazerooni (ORCID: https://orcid.org/0000-0003-3223-2597)
- Hyder A. Jinnah (ORCID: https://orcid.org/0000-0003-1531-3969)
- Virgilio Gerald H. Evidente (ORCID: https://orcid.org/0000-0001-6341-6933)
- Marta Banach
- Peter McAllister (ORCID: https://orcid.org/0000-0003-4965-7700)
Institutions
- Jagiellonian University (PL)
- University of Bonn (DE)
- Emory University (US)
- Quest Research Institute (US)
- Southwest Center for Chronic Disease (US)
- ESI Group (United States) (US)
- New England Institute for Neurology and Headache (US)
- Michigan Ear Institute (US)
- Covance (United States) (US)
- Gdańsk Medical University (PL)
Publication Details
- Journal
- Movement Disorders Clinical Practice
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1002/mdc3.70104
- Citations
- 1
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Revance